Gragoudas ES, Adamis AP, Cunningham ET Jr., Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805–2816. https://doi.org/10.1056/NEJMoa042760

Article  PubMed  CAS  Google Scholar 

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus Verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444. https://doi.org/10.1056/NEJMoa062655

Article  PubMed  CAS  Google Scholar 

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431. https://doi.org/10.1056/NEJMoa054481

Article  PubMed  CAS  Google Scholar 

Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF (2013) Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 120:122–129. https://doi.org/10.1016/j.ophtha.2012.07.042

Article  PubMed  Google Scholar 

Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL (2016) Five-year outcomes with anti-vascular endothelial growth factor treatment of Neovascular Age-Related Macular Degeneration: the comparison of age-related Macular Degeneration treatments trials. Ophthalmology 123:1751–1761. https://doi.org/10.1016/j.ophtha.2016.03.045

Article  PubMed  Google Scholar 

Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and Bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908. https://doi.org/10.1056/NEJMoa1102673

Article  PubMed  CAS  Google Scholar 

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) Intravitreal Aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548. https://doi.org/10.1016/j.ophtha.2012.09.006

Article  PubMed  Google Scholar 

Ohji M, Lanzetta P, Korobelnik JF, Wojciechowski P, Taieb V, Deschaseaux C, Janer D, Tuckmantel C (2020) Efficacy and treatment burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab treat-and-extend regimens at 2 years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and matching-adjusted Indirect comparison. Adv Ther 37:2184–2198. https://doi.org/10.1007/s12325-020-01298-x

Article  PubMed  PubMed Central  Google Scholar 

Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G (2016) Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med 8:1265–1288. https://doi.org/10.15252/emmm.201505889

Article  PubMed  PubMed Central  CAS  Google Scholar 

Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729–740. https://doi.org/10.1016/s0140-6736(22)00010

Article  PubMed  CAS  Google Scholar 

Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, Watanabe Y, Yamamoto A, Wakatsuki Y, Onoe H, Wakugawa S, Terao N, Hasegawa T, Hashiya N, Kawai M, Maruko R, Itagaki K, Honjo J, Okada AA, Mori R, Koizumi H, Iida T, Sekiryu T (2023) Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep 13:8747. https://doi.org/10.1038/s41598-023-35759-4

Article  PubMed  PubMed Central  CAS  Google Scholar 

Matsumoto H, Hoshino J, Nakamura K, Nagashima T, Akiyama H (2023) Short-term outcomes of intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 261:2945–2952. https://doi.org/10.1007/s00417-023-06116-y

Article  PubMed  CAS  Google Scholar 

Matsumoto H, Hoshino J, Nakamura K, Akiyama H (2024) One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration. Jpn J Ophthalmol 68:83–90. https://doi.org/10.1007/s10384-023-01040-4

Article  PubMed  CAS  Google Scholar 

Hara C, Suzue M, Fujimoto S, Fukushima Y, Sayanagi K, Nishida K, Maruyama K, Sato S, Nishida K (2024) Comparison of Loading dose between Aflibercept and Faricimab for Neovascular Age-Related Macular Degeneration. J Clin Med 13. https://doi.org/10.3390/jcm13020385

Tanaka A, Hata M, Tsuchikawa M, Ueda-Arakawa NU, Tamura H, Miyata M, Takahashi A, Kido A, Muraoka Y, Miyake M, Ooto S, Tsujikawa A (2024) Short-term outcomes of 3 monthly intravitreal Faricimab on different subtypes of Neovascular Age-Related Macular Degeneration. Clin Ophthalmol 18:507–516. https://doi.org/10.2147/opth.S448507

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rosenbaum PR, Rubina DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70(1):41–55

Article  Google Scholar 

Austin PC (2011) An introduction to Propensity score methods for reducing the effects of confounding in Observational studies. Multivar Behav Res 46:399–424. https://doi.org/10.1080/00273171.2011.568786

Article  Google Scholar 

Mori R, Honda S, Gomi F, Tsujikawa A, Koizumi H, Ochi H, Ohsawa S, Okada AA (2023) Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial. Jpn J Ophthalmol 67:301–310. https://doi.org/10.1007/s10384-023-00985-w

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lim JI, Margaron P, Souverain A, Yang M, Kotecha A, Willis JR, Patel S, Khanani AM, Bakri SJ (2023) How Effective Is Anti–Ang-2 and Anti-VEGF (Faricimab) for Neovascular AMD With Pigment Epithelial Detachments? AAO 2023

Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS (2016) A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol 100:914–917. https://doi.org/10.1136/bjophthalmol-2015-306987

Article  PubMed  Google Scholar 

Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P, Fajnkuchen F, Tadayoni R (2011) Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 31:26–30. https://doi.org/10.1097/IAE.0b013e3181de5609

Article  PubMed  CAS  Google Scholar 

Oshima Y, Deering T, Oshima S, Nambu H, Reddy PS, Kaleko M, Connelly S, Hackett SF, Campochiaro PA (2004) Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol 199:412–417. https://doi.org/10.1002/jcp.10442

Article  PubMed  CAS  Google Scholar 

Benest AV, Kruse K, Savant S, Thomas M, Laib AM, Loos EK, Fiedler U, Augustin HG (2013) Angiopoietin-2 is critical for cytokine-induced vascular leakage. PLoS ONE 8:e70459. https://doi.org/10.1371/journal.pone.0070459

Article  PubMed  PubMed Central  CAS  Google Scholar 

Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P (2013) Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 120:1046–1056. https://doi.org/10.1016/j.ophtha.2012.10.014

Article  PubMed  Google Scholar 

Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL (2019) Effect of Ranibizumab and Aflibercept on Best-corrected visual acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: a Randomized Clinical Trial. JAMA Ophthalmol 137:372–379. https://doi.org/10.1001/jamaophthalmol.2018.6776

Article  PubMed  PubMed Central  Google Scholar